Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 17, 2017 - Issue 9
Submit an article Journal homepage
2,158
Views
8
CrossRef citations to date
0
Altmetric
Editorial

To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question

Emanuele D’AmicoDepartment of Neurology, MS center, Padova, ItalyCorrespondence[email protected]
View further author information
,
Tjalf ZiemssenCenter of Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, GermanyORCID Iconhttp://orcid.org/0000-0001-8799-8202View further author information
ORCID Icon &
Salvatore CottoneMS Center Department, Neurology A.O.O.R., Villa Sofia-Cervello, Palermo, ItalyView further author information
Pages 847-849 | Received 19 Mar 2017, Accepted 07 Jun 2017, Published online: 16 Jun 2017

References

  • Revesz T, Kidd D, Thompson AJ, et al. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 1994 Aug;117(Pt 4):759–765.
  • Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 83:278–286.
  • Sand IK, Krieger S, Farrell C, et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014 Feb 3;PMID:24493475.
  • Davies F, Wood F, Brain KE, et al. The transition to secondary progressive multiple sclerosis: an exploratory qualitative study of health professionals’ experiences. Int J MS Care. 2016 Sep-Oct;18(5):257–264.
  • Oh J, O’Connor PW. Established disease-modifying treatments in relapsing-remitting multiple sclerosis. Curr Opin Neurol. 2015 Jun;28(3):220–229.
  • Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 2017 Apr 1;74(4):459–469.
  • Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3):209–220.
  • Shirani A, Zhao Y, Petkau J, et al. Multiple sclerosis in older adults: the clinical profile and impact of interferon betatreatment. Biomed Res Int. 2015;2015:451912. DOI:10.1155/2015/451912
  • Presas S, Hervás-Garcia JV, Ramo-Tello C. Stopping disease modifying therapy in multiple sclerosis patients (P3.113). Neurology. 2016 April 5;86(16 Supplement):P3.113.
  • Siger M, Durko A, Nicpan A, et al. Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity. J Neurol Sci. 2011 Apr 15;303(1–2):50–52.
  • Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol. 2004 Aug; 56(2):303–306.
  • Kister I, Spelman T, Alroughani R, et al. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1133–1137.
  • Bsteh G, Feige J, Ehling R, et al. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors. Mult Scler. 2016;1:1352458516675751.
  • Ontaneda D, Fox RJ. Progressive multiple sclerosis. Curr Opin Neurol. 2015 Jun;28(3):237–243.
  • Marziniak M, Meuth S. Current perspectives on interferon beta-1b for the treatment of multiple sclerosis. Adv Ther. 2014;31(9):915–931.
  • Hassoun L, Eisele J, Thomas K, et al. Hands on Alemtuzumab-experience from clinical practice: whom and how to treat. Mult Scler Demyelinating Disord. 2016;1:10.
  • American Academy of Neurology (AAN). Annual meeting. emerging science session poster 009. Presented. 2016. April 19, 2016.
  • Kappos L, Bar-Or A, Cree B, et al. Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study. ECTRIMS Online Library. ECTRIMS 2016, September 2016;3(suppl): pp. 1–917.
  • Giovannoni G, Cutter G, Pia-Sormani M, et al. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Mult Scler Relat Disord. 2017;12:70–78.
  • Butler M, Forte ML, Schwehr N, et al. Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis. Editors Rockville (MD): Agency for Healthcare Research and Quality (US). 2015 Apr. Report No.: 15 EHC012-EF.
  • Ziemssen T, Kern R, Thomas K. Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. BMC Neurology. 2016;16:124.
  • Ziemssen T, Hillert J, Butzkueven H. The importance of collecting structured clinical information on multiple sclerosis. BMC Medicine. 2016;14(1):81–81.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.